Solanezumab (Solanezumab, LY-2062430) - a drug for the treatment of Alzheimer's disease , developed by Eli Lilly . The drug has not passed phase 3 clinical trials.
| Solanesumab | |
|---|---|
| Solanezumab | |
| Chemical compound | |
| Gross formula | C 6396 H 9922 N 1712 O 1996 S 42 |
| Molar mass | 144.1 kDa |
| Cas | |
| Drugbank | |
| Route of administration | |
| solution for intravenous administration | |
| Other names | |
| Solanezumab | |
Content
Pharmacological action
Solanesumab is a monoclonal antibody that aggregates with the central portion of amyloid beta. The drug is administered intravenously, 1 time per week. The recommended dose is 400 mg.
Drug Release Form
Solution for intravenous administration.
See also
- Alzheimer's disease
- Bapineizumab